Key points for investors:
- Leadership: Founder Gordon Sanghera stepped down as CEO after 21 years and will stay on in an advisory role through early 2027. Francis Van Parys has joined as incoming CEO to scale the business into regulated and commercial end markets.
- Strong FY25 performance: Revenue £223.9m, +24.2% at constant currency (above guidance), with >20% growth across all regions. 70% of revenue from consumables (flow cells & kits). Company finished FY25 with £302.8m cash and no debt.
- Margin and profitability progress: Reported gross margin 58.6% (see-through nearer ~61%). Improvements driven by pricing (CapEx-first model) and PromethION yield/recycling; FY26 gross margin guidance is 62%. Adjusted OpEx grew only ~1% in FY25; adjusted EBITDA loss improved by £31.2m (26%). Management reiterates adjusted EBITDA breakeven target in 2027 and cash-flow breakeven in 2028, with a minimum cash runway of >£100m.
- FY26 guidance and drivers: Revenue guidance +21% to +25% (constant currency). Guidance assumptions include continued applied-market adoption (clinical, biopharma QC, industrial), some subdued research demand (notably in the U.S. and China), and execution risks around product transitions (e.g., P2 Solo discontinuation / P2i conversion).
- Strategic focus and product priorities: Following a strategic review, the company is prioritizing higher-return segments (~$13–14bn TAM across priority segments), reallocating commercial and R&D resources accordingly. Decisions include pausing/commercially discontinuing ElysION, discontinuing P2 Solo sales, and concentrating on P2i, P24, GridION Q-line V2 (H2 2026) and updated PromethION developments (product timing pushed to late 2027 for some launches). Key technology advantages emphasized: native direct DNA/RNA sequencing, long reads, real-time streaming, adaptive sampling, and planned PromethION redesign for reuse.
- Innovation roadmap & medium-term opportunities: Continued improvements in throughput, accuracy and workflows (adaptive sampling, direct RNA/mods, proteomics peptide mapping progressing). Proteomics / true protein sequencing viewed as medium-term (3–5 years) opportunity; peptide mapping may generate nearer-term revenue opportunities.
- Operational & working capital improvements: Inventory down (~£18m reduction), improved working capital, ongoing focus on recycling rates (PromethION benefit expected to increase), and ERP/CRM improvements to support scale.
- Risks & uncertainties: One-off headwinds in FY25 (inventory obsolescence, FX) may not repeat; China export restrictions and competitive dynamics; timing/phasing risks tied to product transitions; geopolitical events (Middle East) could affect a small but central supply-chain exposure (~3% revenue).
Sign In
Buy ONTTF
